This directory serves as a resource listing of active biotech that develop therapeutics, diagnostics and/or medtech. The companies listed in this directory are not representative of the companies that are active members of the Biotech and Money community.

Add / Amend your company listing for free
(only active biotech ie. therapeutic, diagnostic and medtech companies are eligible for listing)

Search by Country
13therapeutics is a research and drug development company identifying and characterizing novel anti-inflammatory peptide therapeutics for unmet medical needs with high commercial potential. P13 is the company's most advanced peptide and is being tested for treatment of Acute Otitis Media (AOM) and other inflammatory conditions. Other peptides are under evaluation for a variety of autoimmune and inflammatory diseases.
1molar inc. is a biomedical technology company focused on neural regeneration after spinal cord injury and ischemic stroke. It strives to impact lives through the discovery, development, commercialization, and manufacturing of novel therapeutics on this area. The company leverages its expertise in neuroscience, synthetic biology and tissue engineering to produce product candidates designed to stimulate regeneration.
2B BlackBio, S.L. develops and markets solutions for personalized medicine based on genetics, genomics, and proteomics. The company offers solutions in the areas of metabolic disorders, oncology, cardiovascular diseases, microbiology, pharmacogenetics, and wellness. It offers various microbiology products, such as a sepsis kit to identify bacteria from blood cultures; a fungal ID kit for the diagnostic of clinically relevant fungal species; and a bacterial antibiotic resistance-virulence factors kit to indentify the principal drug resistances and virulence factors in pathogenic bacteria by multiplexed microsequencing.
Menlo Park
3-V Biosciences is a biopharmaceutical company focused on discovering and developing novel therapeutics that modulate key pathways for the treatment of oncology and infectious disease.
3B Pharmaceuticals (3BP) is a leader in peptide-based drug discovery and development. The company's core expertise is ranging from hit identification to early clinical development. 3BP's technologies have been validated in projects with industrial and academic partners. Besides ongoing peptide drug discovery partnerships 3BP is developing proprietary targeted radiopharmaceuticals (oncology) and synthetic affinity ligands for protein downstream processing.
3SBio is a fully integrated, a biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China. The company focus on nephrology, oncology, supportive cancer care, inflammation and infectious diseases.
4-Antibody is a biopharmaceutical company with a powerful fully-human antibody drug-discovery technology platform. The Company is making this technology available to pharmaceutical partners and is also using it to generate a proprietary pipeline of antibody therapeutic drugs. The proprietary discovery engine is the in-vitro Retrocyte Display
4P Therapeutics is a company conducting research and development of novel transdermal drug delivery technologies and products. They work with their partners to develop transdermal products with formulations of small and large molecules including biologics. Their world leading experience in this focused area allows them to efficiently evaluate and utilize the appropriate transdermal technology for a particular drug formulation. They are not a one technology platform company but create product IP from combinations of known technologies such as microneedles and microporation and new formulations of drugs. They conduct preclinical and early stage clinical studies at our company headquarters in Norcross (Atlanta) Georgia. Their model allows their partners to get key proof of concept data efficiently and effectively (low cost short timeline) and mitigate significant risk before the necessary higher development spend.
4SC (ISIN DE0005753818) discovers and develops targeted, small-molecule drugs for the treatment of diseases with a high unmet medical need in various cancer and autoimmune indications. These drugs are intended to provide patients with innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The company's pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with leading pharmaceutical companies.

Founded in 1997, 4SC currently has 83 employees and has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.

4SC Discovery GmbH is a fully owned subsidiary of 4SC. It was incepted in December 2011 in order to provide fully integrated drug discovery services and innovative preclinical products from idea to IND.
A&G Pharmaceutical discovers, develops, and commercializes innovative personalized medicine products that improve screening, monitoring, and targeted treatment of cancer and other human diseases. Company's lead drug/test products in development target breast cancer based on a unique biomarker known as GP88, or progranulin (GP88/PGRN), which is produced by breast cancer tumors and is used to help the cancer grow and proliferate.
A&G Pharmaceutical is a theranostics company creating and developing monoclonal antibodies to cancer-specific targets as a basis for novel therapeutic and diagnostic products. The company is currently advancing a near-term opportunity to develop and commercialize a line of diagnostic test kits that will improve early detection, diagnosis, and treatment of breast cancer based on GP88, a patented and proprietary growth factor discovered by A&G researchers.
Redwood City
A.P. Pharma is a specialty pharmaceutical company developing products using its proprietary Biochronomer? polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks. The Company's lead product candidate, APF530, is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting.